Immunic appoints Erik Lundgren as CEO; Daniel Vitt resigns as CEO but remains on board

IMMUNIC, INC.

Erik Lundgren appointed CEO effective June 1, 2026; previously SVP at Genentech/Roche, led Ocrevus launch.
Daniel Vitt resigns as CEO but retains board seat and responsibility for scientific strategy.
Lundgren receives base salary $685K, target bonus 60%, and initial option for 1M shares under inducement plan.
Phase 3 ENSURE trial in relapsing MS expected data readout by year-end 2026; Lundgren to lead toward potential NDA and commercialization.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erik Lundgren

Chief Executive Officer

IMUX · IMMUNIC, INC.

Effective: 2026-06-01
Filed: May 27, 2026, 7:00 AM ET

On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the "Company") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erik Lundgren was appointed as Chief Executive Officer at IMMUNIC, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the "Company") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.

View on SEC.gov

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-26-000696

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.